Restoril

Product manufactured by Specgx Llc

Application Nr Approved Date Route Status External Links
NDA018163 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Restoril ™ (temazepam) Is Indicated For The Short-Term Treatment Of Insomnia (generally 7 To 10 Days). For Patients With Short-Term Insomnia, Instructions In The Prescription Should Indicate That Restoril ™ (temazepam) Should Be Used For Short Periods Of Time (7 To 10 Days). The Clinical Trials Performed In Support Of Efficacy Were 2 Weeks In Duration With The Final Formal Assessment Of Sleep Latency Performed At The End Of Treatment.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Temazepam TEMAZEPAM ZINC896634

Comments